Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2023_Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium
Histopathology 2023;82:1105-1111
En savoir plus
Lysa
2023_Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
Blood 2023;141:1971-1981
En savoir plus
Lysa
2023_Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing
Leukemia 2023;37:1388-1391
En savoir plus
Lysa
2023_Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data
2023;7:e873
En savoir plus
Lysa
2023_Dissemination patterns of Hodgkin lymphoma using a probability network model based on [18F]-FDG PET/CT
Eur J Nucl Med Mol Imaging 2023;50:1414-1422
En savoir plus
Lysa
2023_Données et preuves en vie réelle dans l’évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ?
2023;78:
En savoir plus
Lysa
2023_Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment
Hemasphere 2023;7:e863
En savoir plus
Lysa
2023_Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?
Br J Haematol 2023;200:13-14
En savoir plus
Lysa
2023_Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment
Br J Haematol 2023;201:857-864
En savoir plus
Lysa
2023_Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study
Br J Haematol 2023;201:256-266
En savoir plus
Lysa
2023_How molecular advances may improve the diagnosis and management of PTCL patients
Front Oncol 2023;13:1202964
En savoir plus
Lysa
2023_High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma
Blood Adv 2023;7:7331-7345
En savoir plus
Lysa
2023_Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
Haematologica 2023;108:171-180
En savoir plus
Lysa
2023_LYSA_Randomized Phase III Trial Evaluating Sub-Cutaneous Rituximab for the First Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
J Clin Oncol . 2023 Apr 18;JCO2202327. doi: 10.1200/JCO.22.02327.
En savoir plus
Lysa
2023_LYSA_High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
DOI: 10.1200/JCO.22.01780
En savoir plus
Lysa
2023_LYSA_Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
DOI: 10.3324/haematol.2022.281226
En savoir plus
Lysa
2023_LYSA_Central nervous system relapse in younger patients with diffuse large B-cell lymphoma – a LYSA and GLA/ DSHNHL analysis
doi: 10.1182/bloodadvances.2022008888.
En savoir plus
Lysa
2022_LYSA_From Stem Cell Transplantation to CAR-T Therapy in Relapse-Refractory Diffuse Large B-Cell Lymphoma
doi.org/10.18103/mra.v10i8.3014
En savoir plus
Lysa
2022_LYSA_Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?
doi: 10.1111/bjh.18468
En savoir plus
Lysa
2022_LYSA_Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy. A DESCAR-T analysis
doi: 10.1182/blood.2022016945.
En savoir plus
Calym
HemSys_Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase
Leukemia & Lymphoma, 59:12, 2812-2820, DOI: 10.1080/10428194.2018.1441408
En savoir plus
Calym
HemSys_IGHV segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies
Haematologica 2018;103(5):e207-e210; https://doi.org/10.3324/haematol.2017.177444.
En savoir plus
Calym
HemSys_Diagnostic value of 18-F fluorodeoxyglucose PET/CT and bone scan in Schnitzler syndrome
Autoimmunity, 52:7-8, 264-271, DOI: 10.1080/08916934.2019.1680649
En savoir plus
Calym
HemSys_Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)
Br J Haematol, 179: 439-448. https://doi.org/10.1111/bjh.14881
En savoir plus